Core Viewpoint - High-yielding dividend healthcare stocks are positioned as attractive investment options for investors seeking passive income, especially with the potential for interest rate cuts on the horizon [2]. Group 1: Investment Rationale - The healthcare sector is characterized by aging populations, recession resilience, and continuous innovation, making it a structurally sound long-term growth area [6]. - The global population over 65 is expected to double in the coming decades, driving sustained demand for medical services and products [8]. - Technological advancements in areas such as gene therapy and AI diagnostics are creating new revenue streams for healthcare companies [5]. Group 2: Company Highlights - **Bristol-Myers Squibb (NYSE: BMY)**: A biopharmaceutical company with a reliable 4.10% dividend, focusing on transformative medicines across various therapeutic areas [9]. - **Healthpeak Properties (NYSE: DOC)**: A REIT investing in healthcare real estate, offering a solid 7.01% dividend and rated highly by analysts [13]. - **Merck (NYSE: MRK)**: A major player in the healthcare industry with a 2.79% dividend, known for its consistent dividend growth over 15 years [16]. - **Pfizer (NYSE: PFE)**: Offers a 6.46% dividend, with strong growth potential from non-COVID products and a promising GLP-1 product launch [21][24]. - **Sanofi (NYSE: SNY)**: A France-based healthcare company with a 4.93% dividend, focusing on patient needs and therapeutic solutions [25].

Core Insights - The article discusses the evolution of the market and the rise of thematic funds, emphasizing the potential of mixing sector ETFs to achieve thematic exposure without the risks associated with single stock investments [1] Thematic Investing Through a Sector Lens - Thematic investing can enhance portfolio diversification and capture transformative trends across industries, including: - **Fintech & Blockchain**: Evolution in the financial sector with digital payment processing and asset tokenization [1] - **Industrial Revitalization**: Automation in manufacturing and increased infrastructure spending due to shifts in global supply chains [1] - **Healthcare Innovation**: Transformative changes in healthcare driven by technology advancements and demographic shifts [1] - **Artificial Intelligence & Robotics**: A convergence of technology, communications, and utilities sectors to support AI demands [1] AI: A Sector Investing Use Case - An example of capturing the AI theme through a balanced sector portfolio is provided, suggesting an equal-weighted blend of: - **Technology Select Sector SPDR ETF (XLK)** - **Communication Services Select Sector SPDR ETF (XLC)** - **Utilities Select Sector SPDR Fund (XLU)** [1] - This strategic mix allows investors to participate in the AI boom while managing volatility and concentration risks associated with high-multiple tech stocks [1] Advantages of Sector ETFs - State Street's sector ETFs offer a cost-efficient solution with low fees (eight basis points), transparency, intraday flexibility, and tax efficiency compared to thematic funds [1] - Utilizing sector ETFs enables investors to capture growth from secular trends while maintaining the structural stability of core holdings [1]

Core Insights - CLEAR collaborates with Mount Sinai Health System to enhance digital experiences for patients and employees, marking Mount Sinai as the first health system in New York City to deploy CLEAR1, a secure identity platform [1][2][3] Company Overview - CLEAR is a secure identity company with a mission to create safer and easier everyday experiences by connecting individuals to their secure identity [4][7] - Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, employing 48,000 staff across seven hospitals and over 400 outpatient practices [8][9] Technology Implementation - CLEAR1 will provide a unified identity across the Mount Sinai ecosystem, facilitating a seamless identity experience for both employees and patients [2][3] - The platform integrates with core healthcare systems such as EHRs and patient portals, streamlining account creation and access, which has previously led to increased digital check-in adoption and reduced duplicate records [5] Security and Standards - CLEAR1 is certified by the Kantara Initiative for NIST Identity Assurance Level 2 (IAL2) and Authenticator Assurance Level 2 (AAL2), ensuring high-assurance standards for trusted healthcare data exchange [6]

Core Insights - Kyndryl and the University of Liverpool are collaborating to develop next-generation healthcare technologies using AI, specifically through Kyndryl's Agentic AI Framework and the University's research expertise [1] - The initiative aims to enhance patient interaction and healthcare services, particularly for underserved populations, by creating AI-driven solutions such as conversational AI services [1] - The collaboration aligns with the Liverpool City Region's Life Sciences Innovation Zone, positioning the area as a hub for health and life sciences innovation [1] Group 1: Collaboration Details - The partnership will co-develop blueprints for healthcare technologies, focusing on AI projects that improve patient experiences [1] - Phase one of the collaboration will evaluate conceptual AI projects aimed at enhancing patient interaction and healthcare service utilization [1] - The projects will utilize population health datasets and testbed environments to create a library of innovation-ready models [1] Group 2: Impact and Goals - The collaboration seeks to address significant health disparities in the Liverpool area, where life expectancy can differ by up to 15 years between affluent and disadvantaged communities [1] - The initiative aims to provide more preventive and personalized care while effectively targeting resources to assist vulnerable populations [1] - Kyndryl's AI innovation lab, launched in May 2025, will play a crucial role in developing solutions for real-world health challenges [1] Group 3: Institutional Background - Kyndryl is a leading provider of mission-critical enterprise technology services, operating in over 60 countries [1] - The University of Liverpool is a prominent research-intensive institution with an annual turnover of £708.3 million and a research income of £163.1 million [1] - The University is ranked among the top 150 universities globally and is a member of the Russell Group, reflecting its significant academic influence [1]

Have you ever had a person in your life that made you feel whole. Who made you feel seen and special. Have you ever had someone in your life whose words and actions had a lasting impact on your life.Well, for me growing up, that person was my auntie Satie. She did so much for our family and she played such a huge role in my life. Well, for most of her life, my auntie Satie battled with breast cancer.Eventually, she went into remission, but about 30 years later, her cancer came back and sadly she passed away ...

Core Insights - Investment strategist Shay Boloor has identified ten sub-$10 billion market-cap companies poised to benefit from long-term trends leading into 2026, focusing on essential platforms and hard infrastructure rather than short-term narratives [1][19] Company Summaries - **Ondas Holdings (NASDAQ: ONDS)**: Developing a wireless connectivity layer for industrial and autonomous drones, with strong revenue growth momentum and a year-to-date stock increase of over 230% [2][3] - **Cipher Mining (NASDAQ: CIFR)**: Transitioning to a digital infrastructure owner with large-scale power and data-center assets, stock up over 250% year to date [6] - **Jumia Technologies (NYSE: JMIA)**: Refining its e-commerce and logistics model in Africa, with improved order volumes and a stock gain of about 215% [7] - **DigitalOcean Holdings (NYSE: DOCN)**: Regaining investor confidence with strong earnings and positioning as an AI inference cloud, stock up 40% year to date [8] - **IREN Limited (NASDAQ: IREN)**: Expanding compute capacity with record profitability and a nearly 285% stock increase [9] - **ClearPoint Neuro (NASDAQ: CLPT)**: Advancing image-guided navigation platforms for neurosurgeons, with a stock decrease of 18% year to date [10] - **Eos Energy Enterprises (NASDAQ: EOSE)**: Developing zinc-based energy storage systems for high-load environments, stock up 170% year to date [11] - **Navitas Semiconductor (NASDAQ: NVTS)**: Supplies gallium nitride power chips for AI data centers, stock up 145% year to date despite near-term pressures [14] - **Viking Therapeutics (NASDAQ: VKTX)**: Developing GLP-1 therapies for obesity and diabetes, with a stock decrease of about 10% [16] - **TransMedics Group (NASDAQ: TMDX)**: Scaling its organ care system with a focus on logistics, stock up about 90% [18]

THIS IN HER 2026 INVESTMENT THEMES IS LISA THOMAS, MANAGING DIRECTOR AND DEPUTY HEAD OF GLOBAL RESEARCH AT TD COWEN. LISA, GOOD MORNING. GOOD TO SEE YOU. >> HEY, GOOD TO SEE YOU, FRANK.>> SO YOU CAME OUT WITH SOME SOME OUTLOOKS FOR 2026. HOW MUCH OF THIS IS DEPENDENT ON NOT ONLY GETTING A CUT TODAY, BUT THE FED CONTINUING TO CUT. >> YOU KNOW THEY'RE REALLY NOT.THESE ARE THE LONGER TERM THEMES RIGHT. SO EACH YEAR WE REALLY TRY TO PULL BACK THE APERTURE AT TD COWAN AND LOOK AT THE BROAD INVESTMENT THEMES THAT ...

Core Viewpoint - Eledon Pharmaceuticals has experienced significant activity recently, with a focus on their developments and data presented at the ASN conference [2]. Group 1: Company Overview - Eledon Pharmaceuticals is represented by Steve Perrin, President and CSO, at the Guggenheim Healthcare Innovation Conference, following the absence of CEO DA Gros due to travel issues [1]. - The company is in a phase of discussing its journey and recent data, indicating a proactive approach to engaging with stakeholders and investors [2]. Group 2: Recent Developments - The discussion will include insights from last week's ASN conference, highlighting key takeaways and future steps for Eledon Pharmaceuticals [2].

Group 1 - The company has experienced significant momentum following the release of data for brepocitinib in dermatomyositis and Graves' disease, indicating strong market potential for the asset [2] - Brepocitinib is expected to be filed next year and launched in 2027, with anticipation from the Key Opinion Leader (KOL) community and patients [2] - The clinical trial for brepocitinib demonstrated strong efficacy across 10 statistically significant endpoints, marking it as one of the cleanest trials in the CFO's 25-year healthcare career [2][3]

Core Insights - Several companies have emerged as top losers in the market, experiencing significant price movements and changes in stock performance [1] Company Summaries - **Bullfrog AI Holdings, Inc. (NASDAQ:BFRGW)**: The stock price decreased slightly to $0.41, with fluctuations between $0.41 and $0.5, and a market capitalization of approximately $4.2 million. The company remains a notable player in the healthcare sector due to its innovative approach, including licensing agreements with prestigious universities for disease treatment [2][6] - **Boqii Holding Limited (NYSE:BQ)**: The stock price dramatically dropped to $4.06, with a range from $1.62 to $56.1, indicating high volatility. The pet-focused platform in China faced challenges and acknowledged unusual trading activity in its Class A ordinary shares on October 30 and 31, 2025 [3][6] - **Charles & Colvard, Ltd. (NASDAQ:CTHR)**: The stock price adjusted to $0.7, with a market cap of approximately $2.2 million. Known for fine jewelry, including moissanite jewels and lab-grown diamonds, the company continues to innovate in the luxury goods sector [4][6] Industry Trends - Despite facing challenges reflected in their stock prices, these companies continue to innovate and push boundaries in their respective sectors, attracting attention from investors and industry analysts [5]